For example, some reports have suggested that disease progression in iCCAs receiving the IDH1 inhibitor ivosidenib was associated with the induction of PD-L1 in cancer cells, Treg recruitment, and higher PD-1, CTLA-4, and CD80 expression in the TME [29,30]. The gene discussed is IDH1; the disease is cancer.